Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
By F. Fossella, J. R. Pereira, J. von Pawel, A. Płużańska, V. Gorbounova, E. Kaukel, K. Mattson, R. Ramlau, A. Szczesna, P. Fidias and 2 more. Journal of Clinical Oncology, 2003
957 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/749632427a5fe1f11d8215999b642f44b88717f0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009, background): “One trial with three arms that combined docetaxel with either cisplatin or carboplatin, each compared with cisplatin/vinorelbine, found that cisplatin/docetaxel was superior to cisplatin/vinorelbine in terms of survival but that carboplatin/docetaxel was not.(56) Other individual trials found no dif”
- An introduction to multiplicity issues in clinical trials: the what, why, when and how. (2016, background): “vinorelbine and cisplatin) in chemotherapy-naive patients with advanced non small-cell lung cancer.(14) Because both the two treatment arms used the same regimen (docetaxel) and added a platinum agent as an adjunct (cisplatin or carboplatin), they were related with each other.”
- Non-small cell lung cancer: current treatment and future advances. (2016, background): “Median overall survival for patients in these studies was approximately 8–10 months (35-38).”